Trusted Women's Health & OB-GYN Care in Seoul · All-Female Specialists

4.9 Patient Satisfaction

en-US

Tongil OB&GY ClinicHome
Book Consultation
Book Consultation
Patient Guide
SpecialtiesServicesDoctorsOffersArticlesReviewsAbout UsContact Us

Press Release

CIZAR CEO Park Rae-ok: Pioneering Development of Ovarian Cancer Treatment Substance Since 2003

CIZAR CEO Park Rae-ok leads innovative research in cervical and ovarian cancer treatment, advancing HPV suppression solutions despite clinical challenges.

Schedule a Consultation
CIZAR CEO Park Rae-ok: Pioneering Development of Ovarian Cancer Treatment Substance Since 2003

Facing Challenges in Clinical Trials, Product Remains an Adjunct Therapy for Over a Decade

Aiming to Build a “Good Company” That Prioritizes Service Over Profit

By Sunwoo Lee, Korea Economic Daily

Park Rae-ok, CEO of CIZAR and Director of Tongil Obstetrics and Gynecology Clinic, has been at the forefront of developing innovative therapeutic substances targeting ovarian and cervical cancer since 2003. Despite promising scientific breakthroughs, the path toward full pharmaceutical approval has proven to be both costly and time-consuming.

“We have developed a substance capable of destroying cancer cells in cervical and ovarian cancer. However, the enormous cost and time required for new drug approval and clinical trials remain a major obstacle,” Park explained.

In collaboration with Professor Baek Seok-nyeon of the Catholic University Medical School, Park first discovered that components within male seminal fluid possess properties capable of eliminating cancer cells associated with ovarian and cervical cancer. Building on this discovery, Park developed CIZAR, a compound created by removing sperm cells and extracting and concentrating three key components, including zinc.

“As an obstetrics and gynecology specialist, my goal was to develop an effective yet affordable treatment for women suffering from ovarian and cervical cancer,” Park said. “However, without sufficient financial backing, it has been extremely difficult to carry out the clinical trials required for official drug approval.”

Currently, CIZAR is used as an adjunctive treatment for cervical and ovarian cancer. Due to its classification, it has not yet received full approval as a formal therapeutic drug, which also limits the use of specialized medical terminology in its promotion.

Park expressed concern over the broader challenges faced by innovators in the medical field:

“Many advanced technologies and promising products fail to overcome the final hurdles and end up being abandoned.”

Continuing research and development efforts between South Korea and the United States, Park recently drew attention with CIZAR SELAVA, a formulation that demonstrated clinical effectiveness in suppressing the proliferation of HPV (Human Papillomavirus), a primary cause of cervical cancer.

In clinical observations:

  • Patients with external genital condyloma (genital warts) showed improvement after 3 weeks of use

  • Patients experiencing vulvar pain showed improvement after 9 weeks

  • HPV infections were eliminated in treated cases

Reflecting on more than a decade of challenges since founding the company, Park emphasized a mission rooted in purpose rather than profit:

“Although we have faced many difficulties over the past ten years, we have never lost our original goal of pursuing service rather than profit.”

Looking ahead, Park also expressed a commitment to supporting future innovators:

“I hope to help talented individuals who share the same passion for research and development but struggle with similar challenges, so they can realize their dreams.”

About CIZAR

CIZAR is a biotechnology company focused on developing innovative solutions for women’s health, particularly in the areas of cervical and ovarian cancer, antiviral care, and HPV-related conditions.

Tongil OB&GY Clinic

Tongil OB&GY Clinic in Seoul provides trusted women's health care, cervical cancer screening, HPV management, and personalized OB-GYN services led by female specialists.

Treatments

SpecialtiesServicesMedical TeamSpecial OffersMedical Articles

Patient Guide

About UsHow It WorksPatient Reviews

Information & Legal

Contact & LocationSite SearchPrivacy PolicyRefund & Cancellation PolicyTerms of Use

© 2026 Tongil OB&GY Clinic. All rights reserved.

Individual clinical results may vary. Please consult a board-certified specialist.